Sweden Faces Severe Shortage of Estrogen Treatments as Women Turn to Finland

Sweden is currently experiencing a significant shortage of estrogen hormone treatments, affecting thousands of women who rely on hormone patches, gels, and sprays. The scarcity is driven by a global surge in demand for these medications, coupled with production bottlenecks, such as a shortage of plastic pumps for spray forms. This shortage has forced many Swedish women to seek their hormone treatments across the border in Finland, a phenomenon often referred to as "estrogen tourism." Pharmacists in Finnish towns like Tornio report heavy demand for estrogen sprays, though supplies there are also limited.

The underlying causes include Sweden's negotiated low medication pricing, which discourages manufacturers from prioritizing deliveries to the Swedish market in comparison to higher-paying countries. Moreover, the number of women over 45 receiving estrogen therapy in Sweden has doubled, reaching approximately 205,000 – over 8% of this demographic – as recent reevaluations of hormone therapy risks have led to increased prescriptions.

The Swedish government and regulatory agencies are actively seeking solutions. The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has approved a 60% price increase for the hormone patch Estradot to incentivize pharmaceutical companies to focus on Swedish supply. Additionally, the government is exploring domestic drug production options, though these measures require time to materialize.

The Swedish Medical Products Agency has been directed to develop long-term strategies to address the ongoing shortages. Temporary measures under consideration include issuing licenses to drugs without full Swedish approval and recognizing foreign drug labels. Despite these efforts, significant challenges remain, such as managing complex dosage adjustments when patients switch between different estrogen treatments.

Clinics in northern Sweden report patient frustration and resource strain due to interrupted treatments. Midwife Maria Karlström from a menopause clinic highlighted that shortages hamper care for new patients, as considerable time is spent managing the crisis. While alternative oral estrogen tablets are sometimes available, not all women can safely switch formulations.

Overall, the estrogen shortage represents a pressing public health concern affecting women's quality of life and medical care across Sweden, with government agencies actively working to mitigate the impact in the near term.